Jaguar Animal Health, Inc. (NASDAQ:JAGX) Shares Shorted: Short Interest Down 74.2% in September

Posted by Brian Himes on Oct 13th, 2026

Jaguar Animal Health, Inc. (NASDAQ:JAGX – Get Free Report) saw a large decrease in short interest in September. As of September 30th, there was short interest totaling 84,156 shares, a decrease of 74.2% from the September 15th total of 326,132 shares. Based on an average daily trading volume, of 6,733,241 shares, the short-interest ratio is presently 0.0 days. Currently, 24.5% of the company’s stock are sold short.

Jaguar Animal Health Stock Performance

JAGX stock traded down $0.53 during midday trading on Tuesday, reaching $4.11. The stock had a trading volume of 385,884 shares, compared to its average volume of 669,528. The firm has a fifty day simple moving average of $9.37 and a two-hundred day simple moving average of $57.76. Jaguar Animal Health has a 52-week low of $2.35 and a 52-week high of $1,260.00. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.40 and a current ratio of 0.69. The stock has a market cap of $1.40 million, a PE ratio of -0.00 and a beta of -0.11.

Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) last announced its quarterly earnings data on Wednesday, August 19th. The biotechnology company reported ($15.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($782.25) by $766.55. The firm had revenue of $1.23 million during the quarter, compared to analyst estimates of $4.24 million.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on JAGX shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Jaguar Animal Health in a report on Friday, July 17th. Wall Street Zen upgraded shares of Jaguar Animal Health to a “sell” rating in a report on Saturday. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, Jaguar Animal Health presently has a consensus rating of “Sell”.

Check Out Our Latest Research Report on Jaguar Animal Health

About Jaguar Animal Health

(Get Free Report)

Jaguar Animal Health, Inc is a commercial-stage animal health company focused on developing and marketing products for gastrointestinal disorders in companion and production animals. Its research is centered on plant-based medicines, including products derived from the red-barked croton tree, Croton lechleri, traditionally used in South America.

The company’s lead animal health product is Canalevia-CA1, a prescription drug containing crofelemer that received conditional approval from the U.S.